AGL 40.05 Increased By ▲ 0.05 (0.13%)
AIRLINK 132.85 Increased By ▲ 3.32 (2.56%)
BOP 6.90 Increased By ▲ 0.22 (3.29%)
CNERGY 4.60 Decreased By ▼ -0.03 (-0.65%)
DCL 8.90 Decreased By ▼ -0.04 (-0.45%)
DFML 42.99 Increased By ▲ 1.30 (3.12%)
DGKC 84.50 Increased By ▲ 0.73 (0.87%)
FCCL 32.85 Increased By ▲ 0.08 (0.24%)
FFBL 76.87 Increased By ▲ 1.40 (1.86%)
FFL 12.13 Increased By ▲ 0.66 (5.75%)
HUBC 110.25 Decreased By ▼ -0.30 (-0.27%)
HUMNL 14.45 Decreased By ▼ -0.11 (-0.76%)
KEL 5.54 Increased By ▲ 0.15 (2.78%)
KOSM 8.33 Decreased By ▼ -0.07 (-0.83%)
MLCF 39.55 Decreased By ▼ -0.24 (-0.6%)
NBP 66.32 Increased By ▲ 6.03 (10%)
OGDC 199.00 Decreased By ▼ -0.66 (-0.33%)
PAEL 26.30 Decreased By ▼ -0.35 (-1.31%)
PIBTL 7.63 Decreased By ▼ -0.03 (-0.39%)
PPL 159.30 Increased By ▲ 1.38 (0.87%)
PRL 26.24 Decreased By ▼ -0.49 (-1.83%)
PTC 18.45 Decreased By ▼ -0.01 (-0.05%)
SEARL 81.70 Decreased By ▼ -0.74 (-0.9%)
TELE 8.12 Decreased By ▼ -0.19 (-2.29%)
TOMCL 34.40 Decreased By ▼ -0.11 (-0.32%)
TPLP 8.94 Decreased By ▼ -0.12 (-1.32%)
TREET 16.88 Decreased By ▼ -0.59 (-3.38%)
TRG 59.40 Decreased By ▼ -1.92 (-3.13%)
UNITY 27.65 Increased By ▲ 0.22 (0.8%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 10,613 Increased By 206 (1.98%)
BR30 31,863 Increased By 149.7 (0.47%)
KSE100 99,102 Increased By 1774 (1.82%)
KSE30 30,842 Increased By 649.1 (2.15%)

Merck's COVID-19 oral pill molnupiravir has a mechanism of action that can work against Omicron and any other variant, a company executive said on Monday.

"We're very confident that it will effect Omicron ... This mechanism in molecule (will) work for Omicron, and I would imagine against any variant that comes up," Dean Li, president of Merck Research Laboratories, said at J.P. Morgan's annual healthcare conference.

Data on molnupiravir's impact against Omicron is not yet available, but the pill was shown to be 30% effective at reducing hospitalizations and deaths, based on data from 1,433 patients, as per latest data released in November.

India says safety concerns restricting use of Merck COVID pill

However, this data showed significantly less effectiveness as compared to the previous figure of 50%.

The pill had received authorization from the US Food and Drug Administration last month, as well as in several other countries like the UK, Japan and India, with various countries including US signing agreements to buy the drug.

Comments

Comments are closed.